keyword
MENU ▼
Read by QxMD icon Read
search

eribulin

keyword
https://www.readbyqxmd.com/read/27908980/phase-2-study-of-eribulin-in-patients-with-previously-treated-advanced-or-metastatic-soft-tissue-sarcoma
#1
Akira Kawai, Nobuhito Araki, Yoichi Naito, Toshifumi Ozaki, Hideshi Sugiura, Yasuo Yazawa, Hideo Morioka, Akihiko Matsumine, Kenichi Saito, Shun Asami, Kazuo Isu
OBJECTIVE: Eribulin, a microtubule dynamics inhibitor, is approved for the treatment of patients with breast cancer and soft tissue sarcoma. We investigated the efficacy and safety of eribulin in Japanese patients with soft tissue sarcoma. METHODS: This open-label, multicenter, nonrandomized, Phase 2 study enrolled Japanese patients with measurable, advanced/metastatic soft tissue sarcoma of high/intermediate grade and ≥1 prior chemotherapy for advanced disease...
December 1, 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27904013/clinical-benefit-of-eribulin-halaven-%C3%A2-in-the-treatment-of-advanced-soft-tissue-sarcoma-patients-and-the-novel-anti-tumor-mechanisms
#2
Noriyuki Koyama, Shigeru Taniguchi, Kotaro Kodama, Osamu Tohyama, Hiroki Hasegawa, Taro Semba
No abstract text is available yet for this article.
2016: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/27863409/integrating-mechanisms-of-response-and-resistance-against-the-tubulin-binding-agent-eribulin-in-preclinical-models-of-osteosarcoma
#3
Valerie B Sampson, Nancy S Vetter, Wendong Zhang, Pratima U Patil, Robert W Mason, Erika George, Richard Gorlick, E A Kolb
Osteosarcoma is the most frequently occurring bone cancer in children and adolescents. Unfortunately, treatment failures are common. Eribulin is a synthetic microtubule inhibitor that has demonstrated activity in preclinical osteosarcoma models. The effects of eribulin were evaluated in two human osteosarcoma cell lines as well as in eribulin-sensitive and -resistant osteosarcoma xenograft tumors of the Pediatric Preclinical Testing Program (PPTP) by characterizing cell viability, microtubule destabilization, mitotic arrest and mechanism of cell death...
November 15, 2016: Oncotarget
https://www.readbyqxmd.com/read/27805627/breast-cancer-eribulin-effective-against-male-breast-cancer
#4
Peter Sidaway
No abstract text is available yet for this article.
November 2, 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27793935/antitumor-effects-of-eribulin-mesylate-in-gemcitabine-resistant-pancreatic-cancer-cell-lines
#5
Yuka Takezaki, Tsutomu Namikawa, Tsuyoshi Koyama, Eri Munekage, Masaya Munekage, Hiromichi Maeda, Hiroyuki Kitagawa, Kazuhiro Hanazaki
BACKGROUND/AIM: One reason of poor survival rate of patients with pancreatic cancer is the development of chemoresistance. The aim of the present study was to investigate the effects of eribulin mesylate in gemcitabine-refractory advanced pancreatic cancer cell lines. MATERIALS AND METHODS: Three human pancreatic cancer cell lines (AsPC-1, Panc-1, and SUIT-2) and human pancreatic endoderm (hPE) cells were used to evaluate the antitumor effects of gemcitabine and eribulin mesylate...
November 2016: Anticancer Research
https://www.readbyqxmd.com/read/27779690/eribulin-sensitizes-oral-squamous-cell-carcinoma-cells-to-cetuximab-via-induction-of-mesenchymal-to-epithelial-transition
#6
Hiroko Kitahara, Mariko Hirai, Koroku Kato, George Bou-Gharios, Hiroyuki Nakamura, Shuichi Kawashiri
Inhibition of epidermal growth factor receptor (EGFR) signalling has emerged as a new treatment strategy for oral squamous cell carcinoma (OSCC). Previously, we found that loss of EGFR expression in OSCC was associated with epithelial-mesenchymal transition (EMT), and may have functional implications with regard to resistance to cetuximab, a monoclonal anti-EGFR antibody. Eribulin (a microtubule inhibitor) reportedly renders breast cancer less aggressive, and less likely to metastasise, by triggering mesenchymal‑to‑epithelial (MET) transition...
October 21, 2016: Oncology Reports
https://www.readbyqxmd.com/read/27760949/-study-of-the-relationship-between-obesity-and-lymphocytes-in-breast-cancer-patients-undergoing-chemotherapy
#7
Keita Adachi, Shuhei Suzuki, Yuki Masuo, Saki Nagashima, Yukiko Hara, Tomohiro Hirano, Katsuhisa Enomoto, Kenichi Sakurai
Obesitychanges the regulatorymechanisms of the immune system, resulting in impaired immunity. In cancer immune mechanisms, the greater the degree of obesity, the lower the activity of the lymphocytes. Herein, we examined the relationship between obesity and lymphocytes in breast cancer patients undergoing chemotherapy. We recruited 10 recurrent or metastatic breast cancer patients who were administered eribulin. Using bodymass index(BMI), we classified these patients into a non-obese group(BMI<25)and an obese group(BMI>25)...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27760942/-ethinylestradiol-following-everolimus-plus-exemestane-was-effective-in-postmenopausal-endocrine-responsive-metastatic-breast-cancer-a-case-report
#8
Aya Matsuoka, Akira Hirano, Akinori Hattori, Kaoru Ogura, Hiroaki Inoue, Hiroko Yukawa, Shiho Sakaguchi, Natsuko Tanaka, Asaka Kodera, Mari Kamimura, Yoshihiko Naritaka, Tadao Shimizu
A 71-year-old woman diagnosed with left breast cancer underwent mastectomy and axillary dissection in 1987. Pathological findings showed invasive ductal carcinoma that was ER and PgR positive and HER2 negative.5 -FU and tamoxifen were administered for 2 years as adjuvant therapy.Bone metastasis was found in 2002, and endocrine therapy was started, using anastrozole, exemestane, letrozole, medroxyprogesterone acetate, and fulvestrant.However, liver, lung, pleural, penetiral, and lymph-node metastases were observed, and the following chemotherapy regimen was administered: CAF, capecitabine, paclitaxel, vinorelbine, gemcitabine, methotrexate plus mitomycin C, and eribulin...
October 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27746162/diminished-dyrk2-sensitizes-hormone-receptor-positive-breast-cancer-to-everolimus-by-the-escape-from-degrading-mtor
#9
Rei Mimoto, Naoe T Nihira, Shinichi Hirooka, Hiroshi Takeyama, Kiyotsugu Yoshida
Mammalian target of rapamycin (mTOR) inhibitor, everolimus, provides benefit for metastatic hormone receptor positive breast cancer after failure of the endocrine therapy. The present report highlights Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2 (DYRK2) as a predictive marker for everolimus sensitivity. The key node and KEGG pathway analyses revealed that mTORC1 pathway is activated in DYRK2-depleted cells. Everolimus was more effective in DYRK2-depleted cells compared with control cells. In xenograft model, everolimus treatment significantly inhibited tumor growth compared with vehicle or eribulin treatment...
October 13, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27742906/eribulin-in-male-patients-with-breast-cancer-the-first-report-of-clinical-outcomes
#10
Francesco Giotta, Luigi Acito, Giampiero Candeloro, Pietro Del Medico, Gennaro Gadaleta-Caldarola, Guido Giordano, Rossana Gueli, Antonio Lugini, Valentina Magri, Marta Mandarà, Giovanna Masci, Salvatore Pisconti, Mirco Pistelli, Anna Rizzi, Nello Salesi, Alessio Schirone, Giovanni Scognamiglio, Maria Tedeschi, Patrizia Zucchinelli
BACKGROUND: Evidence on the management and treatment of male breast cancer is scant. We report the analysis of a multicenter Italian series of patients with male breast cancer treated with eribulin. To our knowledge, this is the first report on the use or eribulin in this setting. PATIENTS AND METHODS: Patients were retrospectively identified in 19 reference centers. All patients received eribulin treatment, according to the standard practice of each center. Data on the identified patients were collected using a standardized form and were then centrally reviewed by two experienced oncologists...
October 14, 2016: Oncologist
https://www.readbyqxmd.com/read/27721762/combination-chemotherapy-of-mitomycin-c-and-methotrexate-was-effective-on-metastatic-breast-cancer-resistant-to-eribulin-vinorelbine-and-bevacizumab-after-anthracycline-taxane-and-capecitabine
#11
Masahiko Tanabe
Complete cure of metastatic breast cancer (MBC) is still considered difficult even after the development of new drugs. While new drugs have been continuously developed, conventional drugs such as mitomycin C (MMC) and methotrexate (MTX) have become less used. Combination chemotherapy with MMC and MTX (MMC/MTX) was reported to be effective for 9.7-19.4% of 31 patients with human epidermal growth factor receptor type 2 (HER2)-negative MBC who were aggressively treated with anthracycline, taxane, capecitabine, and vinorelbine...
May 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27698565/economic-evaluation-of-eribulin-as-second-line-treatment-for-metastatic-breast-cancer-in-south-korea
#12
Gabriel Tremblay, Unnati Majethia, Janis L Breeze, Ilias Kontoudis, Jeongae Park
BACKGROUND: Metastatic breast cancer (MBC) is associated with poor prognosis, particularly for those patients with human epidermal growth factor receptor (HER2)-negative tumor. Similar to the rest of the world, treatment options are limited in South Korea following first-line chemotherapy with anthracyclines and/or taxanes. This study examined the cost-effectiveness and cost-utility of eribulin in South Korean patients with HER2-negative MBC who have progressed after usage of at least one chemotherapeutic regimen for advanced disease (second-line therapy)...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27688604/efficacy-and-safety-of-eribulin-mesylate-in-advanced-soft-tissue-sarcomas
#13
REVIEW
Jonathan Noujaim, Salma Alam, Khin Thway, Robin Lewis Jones
Despite recent advances in the field, treatment options for metastatic soft tissue sarcoma patients are limited. Eribulin, an antimitotic derived from the natural marine sponge product halichondrin B, is currently approved for the treatment of metastatic breast cancer. Following the promising activity of eribulin in sarcoma in a Phase II trial, the drug was recently compared to dacarbazine in pretreated advanced leiomyosarcoma (LMS) and liposarcoma (LPS) patients in a Phase III trial. Eribulin was associated with a significant 2-month improvement in median overall survival compared to dacarbazine (13...
July 2016: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/27672333/eribulin-in-the-management-of-inoperable-soft-tissue-sarcoma-patient-selection-and-survival
#14
REVIEW
Colin Thomas, Sujana Movva
Patients diagnosed with metastatic soft-tissue sarcoma (STS) have a poor prognosis. Additionally, after failure of first-line therapy, there are relatively few treatment options from which to choose. The novel tubulin-binding drug, eribulin, with a unique mechanism of action from taxanes or vinca alkaloids, has shown clinical activity in several different types of cancers. Eribulin has been approved by the US Food and Drug Administration (FDA) for patients with metastatic breast cancer previously treated with an anthracycline or a taxane and has recently been FDA approved for patients with unresectable or metastatic liposarcoma who have failed a previous anthracycline regimen...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27652155/imatinib-could-be-a-new-strategy-for-pulmonary-hypertension-caused-by-pulmonary-tumor-thrombotic-microangiopathy-in-metastatic-breast-cancer
#15
Ippei Fukada, Kazuhiro Araki, Kokoro Kobayashi, Tomoko Shibayama, Masaru Hatano, Shunji Takahashi, Takuji Iwase, Shinji Ohno, Yoshinori Ito
INTRODUCTION: Pulmonary tumor thrombotic microangiopathy (PTTM) is rare, cancer-related pulmonary complication leading to hypoxia, pulmonary hypertension, and heart failure. The standard treatment for PTTM is not established. However, imatinib, a tyrosine kinase inhibitor of the PDGF receptor, may cause regression of pulmonary hypertension and pulmonary artery remodeling in PTTM. CASE DESCRIPTIONS: We report two cases of PTTM who received an anti-PDGF agent of imatinib for PTTM developed during chemotherapy for metastatic breast cancer...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27639032/costs-associated-with-eribulin-treatment-for-patients-with-metastatic-breast-cancer-in-a-comprehensive-cancer-center-in-france
#16
Aline Hurtaud, Anne Donnadieu, Laurence Escalup, Paul H Cottu, Sandrine Baffert
BACKGROUND: There is no standard recommendation for metastatic breast cancer treatment (MBC) after two chemotherapy regimens. Eribulin (Halaven(®)) has shown a significant improvement in overall survival (OS) in this setting. Its use may however be hampered by its cost, which is up to three times the cost of other standard drugs. We report the clinical outcomes and health care costs of a large series of consecutive MBC patients treated with Eribulin. METHODS: A monocentric retrospective study was conducted at Institut Curie over 1 year (August 2012 to August 2013)...
December 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/27588398/abcb1-and-abcc11-confer-resistance-to-eribulin-in-breast-cancer-cell-lines
#17
Takaaki Oba, Hiroto Izumi, Ken-Ichi Ito
This study aimed to elucidate the mechanisms underlying the resistance of breast cancer to eribulin. Seven eribulin-resistant breast cancer cell lines (MCF7/E, BT474/E, ZR75-1/E, SKBR3/E, MDA-MB-231/E, Hs578T/E, and MDA-MB-157/E) were established. mRNA and protein expression of ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 11 (ABCC11) increased in all eribulin-resistant cell lines compared to the parental cell lines. When ABCB1 or ABCC11 expression was inhibited by small interfering RNA in MCF7/E, BT474/E, and MDA-MB-231/E cells, eribulin sensitivity was partially restored...
August 31, 2016: Oncotarget
https://www.readbyqxmd.com/read/27569274/ramucirumab-with-eribulin-versus-eribulin-in-locally-recurrent-or-metastatic-breast-cancer-previously-treated-with-anthracycline-and-taxane-therapy-a-multicenter-randomized-phase-ii-study
#18
Denise A Yardley, James Reeves, E Claire Dees, Cynthia Osborne, Devchand Paul, Foluso Ademuyiwa, Hatem Soliman, Troy Guthrie, Jay Andersen, Lea Krekow, Janak Choksi, Brooke Daniel, Michael Danso, Anne Favret, Sanjay Oommen, Adam Brufsky, Jane L Bromund, Yong Lin, Ayman B Ibrahim, Paul D Richards
BACKGROUND: Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as third- to fifth-line therapy in women with advanced breast cancer. PATIENTS AND METHODS: In this randomized (1:1), open-label, phase II study, US women aged 18 years or older with 2 to 4 previous chemotherapy regimens for locally recurrent or MBC, previous anthracycline and taxane treatment, and Eastern Cooperative Oncology Group performance status of 0 or 1 received ramucirumab with eribulin or eribulin alone in 21-day cycles (eribulin 1...
December 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27542647/systemic-therapy-for-advanced-soft-tissue-sarcoma
#19
REVIEW
Jennifer Y Sheng, Sujana Movva
Soft tissue sarcomas are rare tumors that present with distant metastasis in up to 10% of patients. Survival has improved significantly because of advancements in histologic classification and improved management approaches. Older agents such as doxorubicin, ifosfamide, gemcitabine, and paclitaxel continue to demonstrate objective response rates from 18% to 25%. Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles...
October 2016: Surgical Clinics of North America
https://www.readbyqxmd.com/read/27521572/arsenic-trioxide-induces-noxa-dependent-apoptosis-in-rhabdomyosarcoma-cells-and-synergizes-with-antimicrotubule-drugs
#20
Michael Torsten Meister, Cathinka Boedicker, Ulrike Graab, Manuela Hugle, Heidi Hahn, Thomas Klingebiel, Simone Fulda
The prognosis of metastatic or relapsed rhabdomyosarcoma (RMS) is poor, highlighting the need of new treatment options. In the present study, we evaluated the in vitro efficacy of arsenic trioxide (ATO) in RMS, a FDA-approved drug used in pediatric leukemia. Here, we report that ATO exerts antitumor activity against RMS cells both as single agent and in combination with microtubule-targeting drugs. Monotherapy with ATO reduces cell viability, triggers apoptosis and suppresses clonogenic survival of RMS cells, at least in part, by transcriptional induction of the proapoptotic BH3-only protein Noxa...
October 28, 2016: Cancer Letters
keyword
keyword
95636
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"